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THE NATIONAL RENAL REGISTRIES of
Australia/New Zealand, the United
States, Canada and Japan have reported
an increasing incidence of end-stage
renal disease (ESRD) of between 3%
and 8% per year between 1993 and
1997.1 Despite improvements in treat-
ment, the mortality of people on dialysis
remains high.2 Annual mortality rates in
the various renal registries range from
10% to 20%.3
The proportion of ESRD patients
referred “late” to a nephrologist (ie,
patients needing to commence dialysis
within three to four months of referral)
varies widely. In developing countries,
the proportion is as high as 62%,4 while
in developed countries it is normally
25%–40%.5-8 Previous US and UK
reports have shown that increasing age
and coexisting illnesses,9 ethnicity10 and
membership of a health maintenance
organisation5 are associated with late
referral.
Late-referral (LR) patients on dialysis
experience greater early morbidity and
higher early mortality. Late referral, asso-
ciated with advanced uraemic symp-
toms, metabolic acidosis, hypertension,
pulmonary oedema and pericarditis, fre-
quently results in emergency haemodial-
ysis using central venous catheters.6-8 It
is also associated with longer6,7 and more
costly6 initial hospitalisation. Early mor-
tality, during the initial 6–12 months on
dialysis, is higher for LR patients,4,11 but
little is known about survival differences
beyond the first year.
The aim of our study was to investigate
whether or not late referral to a nephrol-
ogist influences the rates of transplanta-
tion and mortality among patients who
have survived at least one year’s dialysis.
METHODS
1.Methods
ANZDATA database
The Australia and New Zealand Dialy-
sis and Transplant Registry (ANZ-
DATA) maintains a database of patients
treated by maintenance dialysis or renal
transplantation in Australia.12 All Aus-
tralian renal units treating ESRD supply
data to the Registry. Survey forms are
completed six-monthly for all patients
up to and including the date of death.
The only patients not registered are the
few who die before being established on
a maintenance dialysis or transplant
program. Data on the timing of referral
(ie, whether “late” or “not late”) have
been collected for new patients entered
onto the Registry since 1 April 1995.
Data collected
Between 1 April 1995 and 31 March
2000, we followed up patients with
ESRD to examine the long-term effects
of late referral on both the likelihood of
transplantation and on mortality.
Using the ANZDATA database, we
recorded, for each patient, the timing of
referral, age, sex, primary renal disease,
the presence of selected comorbidities
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ABSTRACT
Objective:  To investigate whether late referral to a nephrologist of patients with 
chronic renal insufficiency influences the likelihood of both transplantation and 
mortality among those who survive at least one year on dialysis.
Design:  Retrospective national cohort study, using data from the Australia and New 
Zealand Dialysis and Transplant Registry database.
Participants:  All patients with end-stage renal disease who started renal 
replacement treatment in Australia between 1 April 1995 and 31 December 1998, 
excluding those who received transplants or who died in their first year of dialysis. 
Patients referred “late” were defined as those who needed to commence dialysis 
within three months of referral to a nephrologist.
Main outcome measures:  Length of patient survival, and whether patients 
received a transplant at any time between one year after starting dialysis and 
completion of the study on 31 March 2000.
Results:  Of the 4243 patients included in the study, 1141 (26.9%) were referred 
late. Late-referral (LR) patients were significantly less likely to receive a transplant in 
their second and subsequent years on dialysis (adjusted rate ratio, 0.78; 95% CI, 
0.64–0.95). LR patients were at significantly increased risk of death after their first 
year on dialysis (adjusted hazard ratio, 1.19; 95% CI, 1.04–1.35).
Conclusions:  Late referral is associated with increased mortality, even among 
those who survive their first year on dialysis. Improving the quality of pre-dialysis 
care might improve access to transplantation and long-term survival. General 
practitioners could minimise late referrals through targeted screening of high-risk 
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recorded at entry to the program,
whether or not the patient was of Indige-
nous origin, and the treatment modality
(haemodialysis, peritoneal dialysis or
transplantation).
LR patients were defined as those
needing to commence dialysis within
three months of referral to a nephrolo-
gist. This definition, consistent with
international nephrology research,7,8,13
reflects the minimum time required to
educate patients regarding treatment
options and to establish permanent vas-
cular access for haemodialysis.
Comorbid illnesses noted were diabe-
tes, ischaemic heart disease, cerebrovas-
cular disease, peripheral vascular disease
and chronic lung disease. Outcomes
were patient survival and whether or not
the patient received a transplant at any
time between one year after starting
dialysis and the completion of the study.
Patients
During the study period, 5590 patients
with ESRD commenced renal replace-
ment treatment (RRT). Excluded from
the analysis were 36 patients (0.6%) who
had started treatment outside Australia
or who were overseas visitors, and 194
patients (3.5%) with ESRD due to rap-
idly progressive glomerulonephritis,
Goodpasture’s syndrome, cholesterol
emboli, haemolytic–uraemic syndrome
or cortical necrosis. (As these conditions
generally have a very short course from
inception to ESRD, contact with renal
services earlier than three months before
commencing RRT would not usually
have been possible.)
In their first year on RRT, fewer LR
patients received a transplant (5.5%
[LR] v 10.6% [non-LR]; P < 0.001) and
more died (15.9% [LR] v 9.4% [non-
LR]; P < 0.001). In order to discount
the short-term hazards of an unplanned
commencement of dialysis, we focused
on patients who survived their first year
on dialysis. We therefore excluded 494
patients (8.8%) who received trans-
plants, 600 patients (10.7%) who died
and 23 patients (0.4%) who were lost to
follow-up within the first year. Our
analysis was based on data for the
remaining 4243 patients.
Within the study period, patients were
followed up to the time of transplanta-
tion, loss to follow-up, or death. Trans-
plantation was chosen as an endpoint for
follow-up, as it  greatly reduces
mortality14 and would therefore distort
the effects of other factors, including late
referral.
Statistical analysis
Statistical analysis was performed using
STATA 7.0 software.15 Using the Cox
proportional hazards model, we calcu-
lated a rate ratio for transplantation and
a hazard ratio for death. Patient survival
was estimated by the Kaplan–Meier
method, with the log rank test used to
compare survival curves. The first year
on dialysis was not included in survival
time, as patients had to survive at least
that period to be included.
Ethics approval
Our study was approved by the Joint
Institutional Ethics Committee of the
Royal Darwin Hospital and the Menzies
School of Health Research. We
obtained the approval of ANZDATA to
analyse data for new patients starting
RRT between 1 April 1995 and 31
December 1998.
RESULTS
1.Results
Of the 4243 patients included in the
study, 1141 (26.9%) were LR patients
(Box 1). Hypertensive renal disease,
other types of primary renal disease and
uncertain diagnoses were more com-
mon in the LR group. Primary
glomerulonephritis, polycystic disease,
analgesic nephropathy and reflux neph-
1: Patient characteristics at start of renal replacement therapy 
(number [%] of patients, unless otherwise specified)
Not referred late (n=3102) Referred late (n=1141)
Age (years)
  Mean ( SD) 56.8 (15.6) 56.1 (16.1)
  Range 0.6–86.1 0.6–88.7
Female patients 1362 (43.9%) 478 (41.9%)
Comorbidities*
  Ischaemic heart disease 1183 (38.1%) 454 (39.8%)
  Cerebrovascular disease 448 (14.4%) 194 (17.0%)
  Peripheral vascular disease 765  (24.7%) 337 (29.5%)
  Chronic airways disease 445  (14.4%) 217 (19.0%)
  Diabetes mellitus 893  (28.8%) 408 (35.8%)
Number of comorbidities
  None 1258  (40.6%) 408 (35.8%)
  One 787  (25.4%) 265 (23.2%)
  Two 487  (15.7%) 201 (17.6%)
  Three 339  (10.9%) 146 (12.8%)
  Four 195  (6.3%) 100 (8.8%)
  Five 35  (1.1%) 21 (1.8%)
Primary renal disease
  Primary glomerulonephritis 1065  (34.3%) 348 (30.5%)
  Diabetes mellitus 640  (20.6%) 290 (25.4%)
  Hypertension 311  (10.0%) 151 (13.2%)
  Polycystic disease 282  (9.1%) 38 (3.3%)
  Analgesic nephropathy 222  (7.2%) 53 (4.7%)
  Reflux nephropathy 163  (5.3%) 25 (2.2%)
  Other diagnoses 264  (8.5%) 121 (10.6%)
  Uncertain 155  (5.0%) 115 (10.1%)
Patients of Indigenous origin 239  (7.7%) 153 (13.4%)
*Comorbid illness categories are not mutually exclusive.
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ropathy were more common in the non-
LR group. The LR group had a greater
burden of comorbid illness.
There were no significant differences
in age or sex between LR and non-LR
patients, but a significantly higher pro-
portion of the LR group was of Indige-
nous origin (13.4% v 7.7%; P < 0.001).
LR patients were also less likely to
receive a transplant in their second and
subsequent years on RRT (unadjusted
rate ratio, 0.71; 95% CI, 0.58–0.86).
This difference remained significant
after adjustment for age, sex, number of
comorbidities, primary cause of renal
disease and Indigenous status (adjusted
rate ratio, 0.78; 95% CI, 0.63–0.95).
Kaplan–Meier survival curves, accord-
ing to timing of referral, showed a signif-
icant difference in survival after the first
year on RRT (P value for log rank test,
<0.001) (Box 2). The mortality rate was
20 deaths (95% CI, 18–22 deaths) per
100 patient-years for the LR group and
15 deaths (95% CI, 14–16 deaths) for
the non-LR group. The unadjusted haz-
ard ratio for death in the LR group
compared with the non-LR group was
1.30 (95% CI, 1.14–1.48). After adjust-
ing for known predictors of mortality
(age, sex, number of comorbidities, pres-
ence of primary renal disease and Indige-
nous status), the hazard ratio for death in
the LR group was still significant (1.19;
95% CI, 1.04–1.35). The hazard ratio
for death was significant even when
Indigenous patients were excluded from
the analysis. Inclusion of a variable that
described the dialysis modality in the
first year of treatment made no signifi-
cant difference.
DISCUSSION
1.Discussion
Our results show unequivocally that late
referral is associated with increased
mortality beyond the initial year of
RRT. The association persists even after
adjusting for known predictors of mor-
tality, suggesting that additional factors
may be involved. A plausible explana-
tion is that late referral may be a reflec-
tion of suboptimal pre-ESRD care,
affecting patient survival before com-
mencement of dialysis and for years
afterwards.
It is possible that the difference in
survival rate between LR and non-LR
patients is related to the level of renal
function at the start of dialysis, which
has been shown to be a determinant of
patient survival.16 If non-LR patients
start treatment earlier in the course of
their chronic renal disease (at a stage
when renal function is significantly less
impaired), subsequent survival on dialy-
sis may be longer. ANZDATA has, since
1998, collected data regarding the level
of renal function at the start of dialysis.
Of patients starting RRT during 1998,
the LR patients (n = 358) had a mean
creatinine clearance of 8.0 mL/min
(SD,  7.1) and non-LR patients (n =
1133) had a mean clearance of 7.9 mL/
min (SD,  3.6), a non-significant dif-
ference.14 Assuming that the results
would have been similar for the other
study years (1995–1997), the observed
survival difference would not appear to
be directly related to the level of renal
function at the start of dialysis.
Incomplete adjustment for interven-
ing and confounding variables may be
part of the explanation for the survival
difference attributed to late referral.
Chandna et al11 have shown that a total
comorbidity severity score is a better
predictor of mortality on RRT than the
number of comorbidities. We were una-
ble to explore this possibility, as ANZ-
DATA does not collect data on the
severity of comorbid illnesses. However,
if late referral is an indicator of subopti-
mal pre-ESRD care, it is plausible that
worse outcomes might be due to inade-
quate management of comorbid ill-
nesses, including vascular disease and
heart failure.
Two previous studies7,8 of the effect
of late referral on long-term survival (at
least five years’ follow-up) found no
significant difference in long-term sur-
vival between LR and non-LR patients.
Another study11 found that unplanned
presentation (which is not the same as
late referral) adversely affected survival.
However, all three studies involved
fewer than 300 patients and had limited
power to detect a significant difference
between LR and non-LR groups. By
contrast, our study, based on a national
cohort, has much greater power. More-
over, because our study (unlike previous
studies) excluded all patients who died
in their first year on dialysis, we were
able to separate the short-term effects of
unplanned commencement of RRT
from the long-term disadvantage arising
from suboptimally managed chronic
renal insufficiency.
2: Kaplan–Meier curves of cumulative survival, by timing of referral
Number of patients at risk at beginning of each year of study
Year 1 Year 2 Year 3 Year 4
LR patients 1141 704 384 132
Non-LR patients 3102 1869 909 318
LR = late referral.
1 2 3 4 5
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Our results suggest that improving the
quality of pre-ESRD care, through
timely referral, might improve long-
term survival on RRT. Angiotensin-
converting enzyme inhibitors,17,18
angiotensin-II-receptor antagonists,19
rigorous blood pressure control20 and
rigorous glycaemic control21 have all
been proven effective in slowing the
progression of chronic renal insuffi-
ciency. However, there have been no
definitive studies demonstrating meth-
ods to reduce mortality in people with
chronic renal impairment.
The continuing high incidence of late
referral seems to indicate that nephrolo-
gists are failing to communicate to phy-
sicians and general practitioners the
importance of optimal pre-ESRD care.
Primary care doctors may be unaware of
the severity of renal insufficiency in
some patients, particularly if serum cre-
atinine level is the only measure used to
monitor renal function.22 Late referral
may stem from uncertainty about the
appropriateness of RRT for a given
patient,22 or the perception that treat-
ment services are not easily accessible to
the patient. In a US survey of GPs who
referred new ESRD patients to a renal
unit, Campbell et al23 found that key
factors delaying referral were lack of
knowledge of guidelines (relating to
timing and indications for referral) and
inadequate communication between
nephrologists and GPs.
Levin13 contends that “many special-
ists (and general practitioners) perceive
nephrologists only as providers of dialy-
sis therapy...[and fail to appreciate] the
utility of nephrological care during early
stages of renal insufficiency”. Although
the Australian Kidney Foundation has
issued guidelines for the care of people
with renal impairment,24 to our knowl-
edge no attempt has been made to
assess the awareness of these guidelines
among GPs and non-nephrologists.
The AusDiab study25 found that
2.5% of Australian adults aged 25 years
or over had significant proteinuria and
that 1.1% had a serum creatinine level
of over 120 mol/L. This suggests that
several hundred thousand Australians
have indicators of renal disease. Screen-
ing studies in Japan indicate that people
with proteinuria are 15 times more
likely than those without proteinuria to
develop renal failure within 10 years.26
We believe that there is sufficient evi-
dence that progression of chronic renal
insufficiency to ESRD can be prevented
to suggest that targeted screening for
renal disease among people in high-risk
groups should be undertaken in general
practice. The most important potential
benefit, despite the absence of strong
evidence, could be reduced mortality
among people with chronic renal insuf-
ficiency.
We suggest that GPs use dipstick uri-
nalysis for proteinuria to screen patients
who have any one of the following risk
factors: age over 50, hypertension, dia-
betes, smoking, family history of renal
disease, or being of Indigenous origin.
Serum creatinine level should be meas-
ured to calculate the glomerular filtra-
tion rate using the Cockcroft–Gault
equation.27 Where appropriate, patients
should be treated aggressively for hyper-
tension, proteinuria and other vascular
risk factors, and, if the glomerular filtra-
tion rate falls below 30mL/min, referred
promptly to a nephrologist.24
We must urgently address the lack of
a strong evidence base in the manage-
ment of patients with chronic renal
insufficiency. These patients need a
continuum of care from the time of
diagnosis to the onset of ESRD. Achiev-
ing optimal treatment will require a true
collaboration between GPs and special-
ist nephrologists.
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